54 results
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
14 Sep 22
Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors
4:01pm
in the biopharmaceutical and biotechnology industries, and currently serves as Head of Biotech Strategy at Lumanity Inc., a global pharmaceutical and biotechnology … has served as Lumanity’s Head of Biotech Strategy since March of 2022. In 1993, Mr. Saltzman founded Defined Health Inc., an asset development
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
7 Dec 20
Regulation FD Disclosure
6:06am
aggressive B-cell malignancies The dual action of BTK degradation and IMiD activity may provide a unique treatment strategy for relapsed/refractory B … an attractive therapeutic strategy in the setting of resistance mutations and an expanded set of B-cell malignancies ©Nurix Therapeutics. All rights reserved
8-K
NRIX
Nurix Therapeutics Inc
21 Jun 21
Departure of Directors or Certain Officers
4:17pm
August 2018 to September 2020 and as Senior Vice President of Strategy and Operations from January 2017 to August 2018. From December 2015 until … November 2016, Ms. Wolff was an independent biotechnology consultant advising clients on drug development for commercial launches and driving strategy
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
14 Oct 20
Regulation FD Disclosure
2:01pm
with other oncology therapies including adoptive cell therapy
Matching the Right Business Strategy with Each NxACT Opportunity ©Nurix Therapeutics. All … Industry leader and DeCART founder Dr. Carl June to lead Scientific Advisory Board Chief Operating Officer, Dana Hammill, former director of strategy
8-K
EX-99.1
airogj
2 Jun 21
Regulation FD Disclosure
7:00am
8-K
EX-99.1
le8f jp9zcrj
14 Oct 20
Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update
4:05pm
424B4
ygc9e
5 Mar 21
Prospectus supplement with pricing info
4:07pm
DEF 14A
u6h2nue
25 Mar 21
Definitive proxy
6:03am
DRS
0e510xhxj0ij9 le6j
22 Feb 21
Draft registration statement
12:00am
8-K
EX-99.1
sdfypxir 9l
6 Oct 22
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update
4:10pm
8-K
EX-99.1
3viwemwq
11 Dec 23
Other Events
12:03pm
8-K
EX-99.1
asbfl3os0bmh7czqi3i
16 Feb 21
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update
4:05pm
8-K
EX-99.2
qrv blrj73760nfk0vai
27 Oct 21
Other Events
7:01am
8-K
EX-99.1
a5sa4hfidqay8up1 rz
13 Apr 23
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:02pm
8-K
EX-99.1
7bqq shzg8r90
12 Oct 23
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
4:03pm
8-K
EX-99.1
dxxx0ax6
13 Jul 21
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
4:12pm